Skip to main content
. 2022 Oct 7;9(5):ENEURO.0218-22.2022. doi: 10.1523/ENEURO.0218-22.2022

Figure 5.

Figure 5.

Altered sleep behavior in Mbnl2 KO mice is selectively modulated with flumazenil (Ro 15-1788). A, Mbnl2 KO mice (N = 13) travel significantly less (t(3.02) = 24.36, p = 0.005, Welch’s t test) and spend a significantly longer time immobile than WT littermates (N = 18; t(2.36) = 31.99, p = 0.02, Welch’s t test). B, Schematic of within-subject design experiment of flumazenil (Ro 15-1788; Ro 15-1788) versus vehicle by oral gavage. Time immobile was analyzed at each hour posttreatment. C, Significant effect of time on total time immobile (F(3,30) = 13.14, p < 0.0001, three-way ANOVA; N = 10) and significant interaction between flumazenil (Ro 15-1788; Ro 15-1788) 30 mg/kg treatment and genotype on total time immobile (F(1,10) = 6.398, p = 0.03, three-way ANOVA) in Mbnl2 KO mice (N = 10). Error bars are ± SEM. Flumazenil (Ro 15-1788) decreased time immobile in Mbnl2 KO mice versus WT mice (Extended Data Fig. 5-1). Full statistical analyses are provided in Extended Data Figure 5-1. Individual plots of WT and Mbnl2 KO mice response to flumazenil (Ro 15-1788) administration are shown in Extended Data Figure 5-2. RNA fragment analyses of Gabrg2L inclusion in mice from experiment are shown in Extended Data Figure 5-3. Full statistical analyses of experiment can be found in Extended Data Figure 5-4.